<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22889374</PMID><DateCompleted><Year>2013</Year><Month>01</Month><Day>04</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1423-0127</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2012</Year><Month>Aug</Month><Day>13</Day></PubDate></JournalIssue><Title>Journal of biomedical science</Title><ISOAbbreviation>J Biomed Sci</ISOAbbreviation></Journal><ArticleTitle>The highly conserved 5' untranslated region as an effective target towards the inhibition of Enterovirus 71 replication by unmodified and appropriate 2'-modified siRNAs.</ArticleTitle><Pagination><StartPage>73</StartPage><MedlinePgn>73</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/1423-0127-19-73</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Enterovirus 71 (EV71) is a highly infectious agent that plays an etiological role in hand, foot, and mouth disease. It is associated with severe neurological complications and has caused significant mortalities in recent large-scale outbreaks. Currently, no effective vaccine or specific clinical therapy is available against EV71.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Unmodified 21 nucleotide small interfering RNAs (siRNAs) and classic 2'-modified (2'-O-methylation or 2'-fluoro modification) siRNAs were designed to target highly conserved 5' untranslated region (UTR) of the EV71 genome and employed as anti-EV71 agents. Real-time TaqMan RT-PCR, western blot analysis and plaque assays were carried out to evaluate specific viral inhibition by the siRNAs.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Transfection of rhabdomyosarcoma (RD) cells with siRNAs targeting the EV71 genomic 5' UTR significantly delayed and alleviated the cytopathic effects of EV71 infection, increased cell viability in EV71-infected RD cells. The inhibitory effect on EV71 replication was sequence-specific and dosage-dependent, with significant corresponding decreases in viral RNA, VP1 protein and viral titer. Appropriate 2'-modified siRNAs exhibited similar RNA interference (RNAi) activity with dramatically increased serum stability in comparison with unmodified counterparts.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Sequences were identified within the highly conserved 5' UTR that can be targeted to effectively inhibit EV71 replication through RNAi strategies. Appropriate 2'-modified siRNAs provide a promising approach to optimizing siRNAs to overcome barriers on RNAi-based antiviral therapies for broader administration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Jun-Xia</ForeName><Initials>JX</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Xijing Hospital, Fourth Military Medical University, 15th Changlexi Road, Xi'an 710032, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nie</LastName><ForeName>Xiao-Jing</ForeName><Initials>XJ</Initials></Author><Author ValidYN="Y"><LastName>Lei</LastName><ForeName>Ying-Feng</ForeName><Initials>YF</Initials></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Chao-Feng</ForeName><Initials>CF</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Dong-Liang</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Biao</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Zhi-Kai</ForeName><Initials>ZK</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Guo-Cheng</ForeName><Initials>GC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>08</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Biomed Sci</MedlineTA><NlmUniqueID>9421567</NlmUniqueID><ISSNLinking>1021-7770</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020121">5' Untranslated Regions</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D020121" MajorTopicYN="N">5' Untranslated Regions</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017124" MajorTopicYN="N">Conserved Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012208" MajorTopicYN="N">Rhabdomyosarcoma</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>8</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>8</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>8</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22889374</ArticleId><ArticleId IdType="pmc">PMC3438048</ArticleId><ArticleId IdType="doi">10.1186/1423-0127-19-73</ArticleId><ArticleId IdType="pii">1423-0127-19-73</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol. 2010;9:1097&#x2013;1105. doi: 10.1016/S1474-4422(10)70209-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70209-X</ArticleId><ArticleId IdType="pubmed">20965438</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng KF, Chen LL, Huang PN, Shih SR. Neural pathogenesis of enterovirus 71 infection. Microbes Infect. 2010;12:505&#x2013;510. doi: 10.1016/j.micinf.2010.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2010.03.006</ArticleId><ArticleId IdType="pubmed">20348010</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Zhu Z, Yang W, Ren J, Tan X, Wang Y, Mao N, Xu S, Zhu S, Cui A, Yan D, Li Q, Dong X, Zhang J, Zhao Y, Wan J, Feng Z, Sun J, Wang S, Li D, Xu W. An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virol J. 2010;7:94. doi: 10.1186/1743-422X-7-94.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-7-94</ArticleId><ArticleId IdType="pmc">PMC2885340</ArticleId><ArticleId IdType="pubmed">20459851</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosoya M, Kawasaki Y, Sato M, Honzumi K, Kato A, Hiroshima T, Ishiko H, Suzuki H. Genetic diversity of enterovirus 71 associated with hand, foot and mouth disease epidemics in Japan from 1983 to 2003. Pediatr Infect Dis J. 2006;25:691&#x2013;694. doi: 10.1097/01.inf.0000227959.89339.c3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.inf.0000227959.89339.c3</ArticleId><ArticleId IdType="pubmed">16874167</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Yeo A, Phoon MC, Tan EL, Poh CL, Quak SH, Chow VT. The largest outbreak of hand; foot and mouth disease in Singapore in 2008: the role of enterovirus 71 and coxsackievirus A strains. Int J Infect Dis. 2010;14:e1076&#x2013;e1081. doi: 10.1016/j.ijid.2010.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2010.07.006</ArticleId><ArticleId IdType="pubmed">20952237</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY. Enterovirus 71 in Taiwan. Pediatr Neonatol. 2008;49:103&#x2013;112. doi: 10.1016/S1875-9572(08)60023-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1875-9572(08)60023-6</ArticleId><ArticleId IdType="pubmed">19054914</ArticleId></ArticleIdList></Reference><Reference><Citation>Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interference-based therapeutics. Nature. 2009;457:426&#x2013;433. doi: 10.1038/nature07758.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature07758</ArticleId><ArticleId IdType="pmc">PMC2702667</ArticleId><ArticleId IdType="pubmed">19158789</ArticleId></ArticleIdList></Reference><Reference><Citation>Bitko V, Barik S. Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses. BMC Microbiol. 2001;1:34. doi: 10.1186/1471-2180-1-34.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2180-1-34</ArticleId><ArticleId IdType="pmc">PMC64570</ArticleId><ArticleId IdType="pubmed">11801185</ArticleId></ArticleIdList></Reference><Reference><Citation>Brzezinska J, D'Onofrio J, Buff MC, Hean J, Ely A, Marimani M, Arbuthnot P, Engels JW. Synthesis of 2'-O-guanidinopropyl-modified nucleoside phosphoramidites and their incorporation into siRNAs targeting hepatitis B virus. Bioorg Med Chem. 2012;20:1594&#x2013;1606. doi: 10.1016/j.bmc.2011.12.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmc.2011.12.024</ArticleId><ArticleId IdType="pubmed">22264759</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavender H, Brady K, Burden F, Delpuech-Adams O, Denise H, Palmer A, Perkins H, Savic B, Scott S, Smith-Burchnell C, Troke P, Wright JF, Suhy D, Corbau R. In Vitro Characterization of the Activity of PF-05095808, a Novel Biological Agent for Hepatitis C Virus Therapy. Antimicrob Agents Chemother. 2012;56:1364&#x2013;1375. doi: 10.1128/AAC.05357-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.05357-11</ArticleId><ArticleId IdType="pmc">PMC3294929</ArticleId><ArticleId IdType="pubmed">22203606</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Cao YL, Yang F, Zhang Y, Wang SH, Liu L. Small interfering RNA effectively inhibits the expression of SARS coronavirus membrane gene at two novel targeting sites. Molecules. 2010;15:7197&#x2013;7207. doi: 10.3390/molecules15107197.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules15107197</ArticleId><ArticleId IdType="pmc">PMC6259191</ArticleId><ArticleId IdType="pubmed">20956884</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhiqiang W, Yaowu Y, Fan Y, Jian Y, Yongfeng H, Lina Z, Jianwei W, Qi J. Effective siRNAs inhibit the replication of novel influenza A (H1N1) virus. Antiviral Res. 2010;85:559&#x2013;561. doi: 10.1016/j.antiviral.2009.12.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2009.12.010</ArticleId><ArticleId IdType="pubmed">20060420</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan EL, Wong AP, Poh CL. Development of potential antiviral strategy against coxsackievirus B4. Virus Res. 2010;150:85&#x2013;92. doi: 10.1016/j.virusres.2010.02.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2010.02.017</ArticleId><ArticleId IdType="pubmed">20214933</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnett JC, Rossi JJ. RNA-based therapeutics: current progress and future prospects. Chem Biol. 2012;19:60&#x2013;71. doi: 10.1016/j.chembiol.2011.12.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chembiol.2011.12.008</ArticleId><ArticleId IdType="pmc">PMC3269031</ArticleId><ArticleId IdType="pubmed">22284355</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin JY, Chen TC, Weng KF, Chang SC, Chen LL, Shih SR. Viral and host proteins involved in picornavirus life cycle. J Biomed Sci. 2009;16:103. doi: 10.1186/1423-0127-16-103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1423-0127-16-103</ArticleId><ArticleId IdType="pmc">PMC2785775</ArticleId><ArticleId IdType="pubmed">19925687</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts J, Deleavey G, Damha M. Chemically modified siRNA: tools and applications. Drug Discov Today. 2008;13:842&#x2013;855. doi: 10.1016/j.drudis.2008.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2008.05.007</ArticleId><ArticleId IdType="pubmed">18614389</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramsen JB, Laursen MB, Nielsen AF, Hansen TB, Bus C, Langkjaer N, Babu BR, Hojland T, Abramov M, Van Aerschot A, Odadzic D, Smicius R, Haas J, Andree C, Barman J, Wenska M, Srivastava P, Zhou C, Honcharenko D, Hess S, Muller E, Bobkov GV, Mikhailov SN, Fava E, Meyer TF, Chattopadhyaya J, Zerial M, Engels JW, Herdewijn P, Wengel J. et al.A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Res. 2009;37:2867&#x2013;2881. doi: 10.1093/nar/gkp106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkp106</ArticleId><ArticleId IdType="pmc">PMC2685080</ArticleId><ArticleId IdType="pubmed">19282453</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin D, Kim SI, Park M, Kim M. Immunostimulatory properties and antiviral activity of modified HBV-specific siRNAs. Biochem Biophys Res Commun. 2007;364:436&#x2013;442. doi: 10.1016/j.bbrc.2007.10.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2007.10.012</ArticleId><ArticleId IdType="pubmed">17963721</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SI, Shin D, Lee H, Ahn BY, Yoon Y, Kim M. Targeted delivery of siRNA against hepatitis C virus by apolipoprotein A-I-bound cationic liposomes. J Hepatol. 2009;50:479&#x2013;488. doi: 10.1016/j.jhep.2008.10.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2008.10.029</ArticleId><ArticleId IdType="pubmed">19155084</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutkiewicz M, Grunert HP, Zeichhardt H, Lena SW, Wengel J, Kurreck J. Design of LNA-modified siRNAs against the highly structured 5' UTR of coxsackievirus B3. FEBS Lett. 2008;582:3061&#x2013;3066. doi: 10.1016/j.febslet.2008.07.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2008.07.051</ArticleId><ArticleId IdType="pubmed">18691577</ArticleId></ArticleIdList></Reference><Reference><Citation>Werk D, Wengel J, Wengel SL, Grunert HP, Zeichhardt H, Kurreck J. Application of small interfering RNAs modified by unlocked nucleic acid (UNA) to inhibit the heart-pathogenic coxsackievirus B3. FEBS Lett. 2010;584:591&#x2013;598. doi: 10.1016/j.febslet.2009.12.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2009.12.007</ArticleId><ArticleId IdType="pubmed">20005874</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmen J, Thonberg H, Ljungberg K, Frieden M, Westergaard M, Xu Y, Wahren B, Liang Z, Orum H, Koch T, Wahlestedt C. Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res. 2005;33:439&#x2013;447. doi: 10.1093/nar/gki193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gki193</ArticleId><ArticleId IdType="pmc">PMC546170</ArticleId><ArticleId IdType="pubmed">15653644</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JR, Tuan YC, Tsai HP, Yan JJ, Liu CC, Su IJ. Change of major genotype of enterovirus 71 in outbreaks of hand-foot-and-mouth disease in Taiwan between 1998 and 2000. J Clin Microbiol. 2002;40:10&#x2013;15. doi: 10.1128/JCM.40.1.10-15.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.40.1.10-15.2002</ArticleId><ArticleId IdType="pmc">PMC120096</ArticleId><ArticleId IdType="pubmed">11773085</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JR, Tsai HP, Chen PF, Lai YJ, Yan JJ, Kiang D, Lin KH, Liu CC, Su IJ. An outbreak of enterovirus 71 infection in Taiwan, 1998. II. Laboratory diagnosis and genetic analysis. J Clin Virol. 2000;17:91&#x2013;99. doi: 10.1016/S1386-6532(00)00079-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1386-6532(00)00079-2</ArticleId><ArticleId IdType="pubmed">10942089</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh MT, Wang SW, Yu CK, Lin KH, Lei HY, Su IJ, Wang JR. A single nucleotide in stem loop II of 5'-untranslated region contributes to virulence of enterovirus 71 in mice. PLoS One. 2011;6:e27082. doi: 10.1371/journal.pone.0027082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0027082</ArticleId><ArticleId IdType="pmc">PMC3206083</ArticleId><ArticleId IdType="pubmed">22069490</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Kong F, Wang B, McPhie K, Gilbert GL, Dwyer DE. Molecular characterization of enterovirus 71 and coxsackievirus A16 using the 5' untranslated region and VP1 region. J Med Microbiol. 2011;60:349&#x2013;358. doi: 10.1099/jmm.0.025056-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jmm.0.025056-0</ArticleId><ArticleId IdType="pubmed">21148280</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim AC, Luhur A, Tan TM, Chow VT, Poh CL. RNA interference against enterovirus 71 infection. Virology. 2005;341:72&#x2013;79. doi: 10.1016/j.virol.2005.06.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2005.06.047</ArticleId><ArticleId IdType="pubmed">16083932</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan EL, Tan TM, Chow VT, Poh CL. Enhanced potency and efficacy of 29-mer shRNAs in inhibition of Enterovirus 71. Antiviral Res. 2007;74:9&#x2013;15. doi: 10.1016/j.antiviral.2007.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2007.01.004</ArticleId><ArticleId IdType="pubmed">17316836</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan EL, Tan TM. Tak Kwong Chow V, Poh CL: Inhibition of enterovirus 71 in virus-infected mice by RNA interference. Mol Ther. 2007;15:1931&#x2013;1938. doi: 10.1038/sj.mt.6300287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.mt.6300287</ArticleId><ArticleId IdType="pubmed">17712333</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z, Yang F, Zhao R, Zhao L, Guo D, Jin Q. Identification of small interfering RNAs which inhibit the replication of several Enterovirus 71 strains in China. J Virol Methods. 2009;159:233&#x2013;238. doi: 10.1016/j.jviromet.2009.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2009.04.002</ArticleId><ArticleId IdType="pubmed">19490979</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu WW, Hsu YY, Yang JY, Kung SH. Selective inhibition of enterovirus 71 replication by short hairpin RNAs. Biochem Biophys Res Commun. 2004;325:494&#x2013;499. doi: 10.1016/j.bbrc.2004.10.062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2004.10.062</ArticleId><ArticleId IdType="pubmed">15530419</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding Y, Chan CY, Lawrence CE. Sfold web server for statistical folding and rational design of nucleic acids. Nucleic Acids Res. 2004;32:W135&#x2013;W141. doi: 10.1093/nar/gkh449.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkh449</ArticleId><ArticleId IdType="pmc">PMC441587</ArticleId><ArticleId IdType="pubmed">15215366</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei X, Liu X, Ma Y, Sun Z, Yang Y, Jin Q, He B, Wang J. The 3C protein of enterovirus 71 inhibits retinoid acid-inducible gene I-mediated interferon regulatory factor 3 activation and type I interferon responses. J Virol. 2010;84:8051&#x2013;8061. doi: 10.1128/JVI.02491-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02491-09</ArticleId><ArticleId IdType="pmc">PMC2916543</ArticleId><ArticleId IdType="pubmed">20519382</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei X, Sun Z, Liu X, Jin Q, He B, Wang J. Cleavage of the adaptor protein TRIF by enterovirus 71 3C inhibits antiviral responses mediated by Toll-like receptor 3. J Virol. 2011;85:8811&#x2013;8818. doi: 10.1128/JVI.00447-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00447-11</ArticleId><ArticleId IdType="pmc">PMC3165803</ArticleId><ArticleId IdType="pubmed">21697485</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu J, Yi L, Zhao J, Yu J, Chen Y, Lin MC, Kung HF, He ML. Enterovirus 71 disrupts interferon signaling by reducing the level of interferon receptor 1. J Virol. 2012;86:3767&#x2013;3776. doi: 10.1128/JVI.06687-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.06687-11</ArticleId><ArticleId IdType="pmc">PMC3302529</ArticleId><ArticleId IdType="pubmed">22258259</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi L, He Y, Chen Y, Kung HF, He ML. Potent inhibition of human enterovirus 71 replication by type I interferon subtypes. Antivir Ther. 2011;16:51&#x2013;58. doi: 10.3851/IMP1720.</Citation><ArticleIdList><ArticleId IdType="doi">10.3851/IMP1720</ArticleId><ArticleId IdType="pubmed">21311108</ArticleId></ArticleIdList></Reference><Reference><Citation>Khaliq S, Jahan S, Pervaiz A. Ali Ashfaq U, Hassan S: Down-regulation of IRES containing 5'UTR of HCV genotype 3a using siRNAs. Virol J. 2011;8:221. doi: 10.1186/1743-422X-8-221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-8-221</ArticleId><ArticleId IdType="pmc">PMC3116492</ArticleId><ArticleId IdType="pubmed">21569449</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanda T, Steele R, Ray R, Ray RB. Small interfering RNA targeted to hepatitis C virus 5' nontranslated region exerts potent antiviral effect. J Virol. 2007;81:669&#x2013;676. doi: 10.1128/JVI.01496-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01496-06</ArticleId><ArticleId IdType="pmc">PMC1797438</ArticleId><ArticleId IdType="pubmed">17079316</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitlin L, Stone JK, Andino R. Poliovirus escape from RNA interference: short interfering RNA-target recognition and implications for therapeutic approaches. J Virol. 2005;79:1027&#x2013;1035. doi: 10.1128/JVI.79.2.1027-1035.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.2.1027-1035.2005</ArticleId><ArticleId IdType="pmc">PMC538575</ArticleId><ArticleId IdType="pubmed">15613331</ArticleId></ArticleIdList></Reference><Reference><Citation>Westerhout EM, Berkhout B. A systematic analysis of the effect of target RNA structure on RNA interference. Nucleic Acids Res. 2007;35:4322&#x2013;4330. doi: 10.1093/nar/gkm437.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkm437</ArticleId><ArticleId IdType="pmc">PMC1934999</ArticleId><ArticleId IdType="pubmed">17576691</ArticleId></ArticleIdList></Reference><Reference><Citation>Low JT, Knoepfel SA, Watts JM, ter Brake O, Berkhout B, Weeks KM. SHAPE-directed discovery of potent shRNA inhibitors of HIV-1. Mol Ther. 2012;20:820&#x2013;828. doi: 10.1038/mt.2011.299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2011.299</ArticleId><ArticleId IdType="pmc">PMC3321596</ArticleId><ArticleId IdType="pubmed">22314289</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W, Hartsough K, Machemer L, Radka S, Jadhav V, Vaish N, Zinnen S, Vargeese C, Bowman K, Shaffer CS, Jeffs LB, Judge A, MacLachlan I, Polisky B. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol. 2005;23:1002&#x2013;1007. doi: 10.1038/nbt1122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt1122</ArticleId><ArticleId IdType="pubmed">16041363</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraynack BA, Baker BF. Small interfering RNAs containing full 2'-O-methylribonucleotide-modified sense strands display Argonaute2/eIF2C2-dependent activity. RNA. 2006;12:163&#x2013;176. doi: 10.1261/rna.2150806.</Citation><ArticleIdList><ArticleId IdType="doi">10.1261/rna.2150806</ArticleId><ArticleId IdType="pmc">PMC1370895</ArticleId><ArticleId IdType="pubmed">16301602</ArticleId></ArticleIdList></Reference><Reference><Citation>Allerson CR, Sioufi N, Jarres R, Prakash TP, Naik N, Berdeja A, Wanders L, Griffey RH, Swayze EE, Bhat B. Fully 2'-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. J Med Chem. 2005;48:901&#x2013;904. doi: 10.1021/jm049167j.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm049167j</ArticleId><ArticleId IdType="pubmed">15715458</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>